Google Ads for Regenerative Medicine: What Works and What Gets Banned

Google Ads for regenerative medicine are possible, but the policy runs straight through the middle of the category. Google's Healthcare and medicines policy prohibits promotion of "speculative and/or experimental medical treatments." It treats cell and gene therapy promotion as off limits unless the advertiser holds the FDA license or approval for that product, and it allows ads that are exclusively educational. Which side of that line a clinic's service falls on decides the campaign.

Most clinics find this out when an ad is disapproved. You can read the rule first and spend the same money on the part of your menu Google will actually run. Organic search covers the treatment-name demand that ads cannot, and the regenerative medicine SEO guide lays that side out.

This guide sorts a regenerative service menu into lanes, shows what each lane can do on Google, and covers the audience, claims, and measurement rules that apply on top. I read every Google and FDA page cited here on October 28, 2026. Google's policy pages show no "last updated" date, and the FDA consumer page is marked current as of April 8, 2024, so check all of them again before you launch.

Key Takeaways

• Google prohibits promotion of speculative and experimental medical treatments. Its cell and gene therapy rule allows promotion only by the entity that holds the FDA license or approval, plus ads that are exclusively educational.
• FDA's consumer page, current as of April 2024, says the only approved stem cell products are blood-forming stem cells from cord blood. FDA has since approved a mesenchymal stromal cell product (Ryoncil, December 2024, for pediatric steroid-refractory acute graft-versus-host disease), so check FDA's list of approved cellular and gene therapy products before you decide. The exception also covers only the license holder, so most in-clinic cell injections cannot use it.
• Sort your menu into three lanes before you build anything: services outside the policy, services in a gray zone, and services squarely inside it.
• Campaigns that work sit on conditions, evaluations, and non-cell services, with treatment-name demand handled by organic search and Google Business Profile.
• Health is a sensitive interest category on Google, which removes Customer Match and advertiser-curated audiences from your remarketing toolkit.
• Landing page claims face a second test. The FTC expects substantiation for health claims, and a testimonial with atypical results is likely deceptive.

What Google's Policy Actually Says

Google's Healthcare and medicines policy has three pieces that matter for regenerative clinics, and each one has a different effect on what you can run.

Sources: Google Ads Healthcare and medicines policy and the July 2022 update on cell and gene therapies.

The history explains why the rule exists. Google's October 2019 policy notice announced the ban globally. It gave non-exhaustive examples, including stem cell therapy, cellular (non-stem) therapy, gene therapy, and "similar forms of regenerative medicine," along with platelet rich plasma, biohacking, and DIY genetic engineering products.

The current policy page I read does not repeat that example list. I would treat the 2019 notice as a signal about how Google thinks about the category.

Why the FDA-Approved Exception Rarely Helps

The U.S. exception sounds like an opening. For most clinics it is closed, because of what FDA has approved.

FDA's consumer page, current as of April 2024, states that the only stem cell products approved for use in the United States consist of blood-forming stem cells derived from umbilical cord blood. They are approved only for blood-production disorders. FDA announced a first mesenchymal stromal cell approval in December 2024, for a narrow pediatric indication, so the approved list is not frozen. The consumer page also says regenerative medicine products "have risks but are often illegally marketed by clinics as being safe and effective."

That matters in two ways.

1. The exception belongs to the license holder. Google's July 2022 update applies it only to entities that hold the relevant FDA license or approval. A clinic that administers a licensed product does not become the license holder, so confirm with Google before assuming the exception reaches your ads.
2. Google and FDA both flag this category. Google's policy and FDA's consumer page both treat clinic-marketed cell products as a risk category.

Whether your clinic's offer is lawful is a question for your counsel. This guide covers what the ad platform will let you promote.

Sort Your Service Menu Into Three Lanes

Twenty years as a software engineer, including work on a platform that went from zero to $500M, left me with one habit: sort inputs before you build on them. A regenerative menu sorts into three lanes, and the lane sets the campaign.

Lane 1: Services outside the cell and gene therapy policy. Think physical medicine, joint pain evaluation, regenerative-adjacent services that involve no cell or gene product, nutrition, and diagnostics. These fall outside the cell and gene therapy rule, though other Google health rules still apply to anything that involves prescribing.

Lane 2: Gray-zone services. Platelet rich plasma is the clearest example. Google's 2019 notice named it. The current policy page does not. I cannot tell you how a given PRP ad will be reviewed today. Treat it as a test lane with a narrow, low-spend campaign and a paper trail of what was submitted.

Lane 3: Cell and gene therapy services. Stem cell and other cellular therapies fall here. Without an FDA license or approval, promotional ads are not available. The only door left is the educational one.

A lane is a decision about risk. Write it down per service, and have counsel confirm your Lane 1 and Lane 2 calls.

What Works in Google Ads for Regenerative Medicine

Campaigns that hold up in this category are built around the patient's problem and the first appointment, with the treatment name left out of the ad promise.

Condition and evaluation campaigns

A patient with knee pain searches for relief and a diagnosis long before they search for a specific injection. Ads for joint pain evaluation, orthopedic consultation, and physical medicine reach that patient and offer something Google will run: an evaluation.

Keep the ad about the visit. The landing page should describe the evaluation, the clinician, and what happens next.

Keep the destination consistent with the ad

In my experience Google reviews the destination as well as the ad. A clean ad that sends traffic to a page selling a Lane 3 therapy hands the reviewer the violation. Build a separate evaluation page for ad traffic and keep Lane 2 and Lane 3 detail on other pages that the ads do not point to.

Keep ad traffic away from any page you are not sure about.

Treatment-name demand belongs to organic search

Patients do search by treatment name, and that demand does not disappear because ads cannot serve it. Own it with content that educates and ranks.

Your Google Business Profile captures the local version of the same searches.

This split is the practical answer to "what works": ads for the problem and the evaluation, organic for the treatment name.

Exclusively educational ads

The educational lane exists in the policy text, and it is narrow by design. Google's wording is "exclusively educational or informational in nature." An ad with a booking offer, a price, or a clinic-specific treatment pitch is not exclusively informational, in my reading.

If you use this lane, write it like a public health notice: what the treatment is, what FDA says about it, and where to find independent information. It will likely earn fewer calls than a promotional ad, and in my judgment it carries less policy exposure.

Audience and Remarketing Limits

Google lists health as a sensitive interest category in its personalized advertising policy. For advertisers in those categories, the policy page says they "are unable to use advertiser-curated audiences," and that Customer Match and your data segments are not supported.

Four things change in practice.

• No Customer Match. Uploading a patient or lead list for targeting is off the table.
• No remarketing lists built from your site visitors, since those are advertiser-curated audiences.
• Predefined Google audiences still work, including in-market segments, affinity, demographics, and location targeting.
• Demand Gen and Discovery campaigns default to advertiser-curated audiences and may be restricted.

The consequence for budget is simple. Search campaigns, where intent comes from the query, carry more of the load for you than they do for an e-commerce advertiser.

Landing Page Claims Face a Second Test

Passing Google's policy review does not clear your page with regulators, and health pages are YMYL content that gets extra scrutiny. The FTC's health products compliance guidance says health benefit claims need "competent and reliable scientific evidence," and that testimonials cannot support claims you could not substantiate directly.

The same guidance says testimonials reporting results more dramatic than typical are likely deceptive, and that a results-may-vary disclaimer does not fix that. Because the category draws regulator attention, three page rules follow.

• State what the evidence supports and cite it, using the language your clinician can defend.
• Describe the process and the evaluation in detail, and keep outcome promises out.
• Use patient stories only when the result shown is what a typical patient can expect, and say what that is.

Google's Misrepresentation policy also lists "claims that entice the user with an improbable result" among unreliable claims. An outcome headline can fail both tests at once.

Authority content helps on this front too. The clinical authority guide covers how to document cases without overpromising.

A 30-Day Plan for a Regenerative Ads Launch

Here is the sequence I would run. The steps are ordered by risk, and each one is small.

1. Week 1: Sort the menu. Put every service in Lane 1, 2, or 3 and get counsel to confirm.
2. Week 1: Read the policy pages above and save dated copies, since the pages show no update date.
3. Week 2: Build one evaluation landing page for ad traffic. Clinician, process, what the first visit covers, one booking path.
4. Week 2: Write condition-led ads for Lane 1 services only. Keep treatment names out of headlines.
5. Week 3: Launch a small search campaign in your service area with a conservative budget and tight geographic targeting.
6. Week 3: Track booked evaluations. Count appointments from the evaluation page.
7. Week 4: Review search terms and add negatives. Review disapprovals and write down the exact wording that triggered each one.
8. Week 4: Decide on a Lane 2 test, if your counsel agrees, as a separate low-budget campaign.

If you want the full build run for you, the paid ads service covers it.

The rest of this specialty lives in the regenerative medicine marketing hub.

Mistakes That Cost Regenerative Clinics Their Ads

• Writing ad copy around the treatment name when the service is in Lane 3.
• Sending ad traffic to a page that sells a Lane 3 therapy.
• Building a remarketing list that the health category does not allow.
• Treating a disapproval as a copy problem when it is a lane problem. Rewording a Lane 3 ad does not change what it promotes.
• Using patient results as the headline. Atypical outcomes create FTC exposure, and the FTC says a disclaimer does not repair them.
• Skipping the dated record. When a policy page changes, you want to show what you read and when.

Your Next Step

This week, list every service on your menu and mark each one Lane 1, Lane 2, or Lane 3. Send that list to your counsel for confirmation before you write a single ad.

Questions practice owners ask

Can a stem cell clinic run Google Ads?

Google prohibits promotion of speculative and experimental treatments and generally prohibits cell and gene therapy promotion unless the advertiser holds the FDA license or approval. Exclusively educational ads are allowed regardless of status. A clinic offering unapproved cell products cannot run promotional ads for them.

Is PRP banned on Google Ads?

Google's October 2019 notice named platelet rich plasma as an example of a prohibited speculative treatment. The current policy page does not list examples, so the present treatment of PRP ads is unclear from the text. Test with a narrow campaign and keep records.

Do I need LegitScript to advertise a regenerative clinic?

Google names LegitScript's Healthcare Merchant Certification for U.S. telemedicine providers, which covers prescribing services. An in-person regenerative clinic is not described by that rule. If you prescribe through telehealth, read the Google policy and LegitScript's healthcare certification page.

Can I bid on stem cell keywords if my ads are educational?

The policy text I read speaks to promotion, and it does not address keyword bids on treatment names. I cannot confirm how a keyword-level review works. Test it narrowly and read disapproval notices.

What do I do if an ad is disapproved?

Read the exact policy named in the notice, decide which lane the service sits in, and fix the destination along with the ad. In my view, repeated resubmission of the same promotion wastes time and adds risk to the account.

Where should the rest of the acquisition effort go?

Into organic search, reviews, and authority content. The AI search and SEO hub covers how to be found when patients ask AI tools about regenerative options.

Mike Kohl, founder of Health Biz Scale | Policy pages read October 28, 2026

This guide is general information, not legal or regulatory advice. Confirm current Google and FDA requirements with a qualified healthcare attorney before launching.